Serina Therapeutics has secured $15 million in gross proceeds through a private placement, with a first tranche set to close on March 20, 2026, and a second tranche potentially adding another $15 million by April 30, 2026. The offering includes common stock and pre-funded warrants priced at $2.25 per share, along with 50% warrant coverage priced at $5.00 per share, which could yield an additional $33.3 million if exercised.

This funding will directly support the registrational study arm of SER-252 under a 505(b)(2) NDA pathway, with dosing already underway in Australia. The Phase 1b study aims to enroll patients in both Australia and the U.S., with a blinded review of the first cohort expected to facilitate progression to the second cohort by Q3 2026. Topline results from the single-ascending dose study are anticipated in early 2027.

For professionals in the longevity field, this development highlights the ongoing investment in innovative therapies and the potential for SER-252 to influence treatment paradigms. I encourage you to read the full article for further insights into Serina’s strategy and the implications for our field.

Source: longevity.technology